Can I read Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome on EtoBox?

Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome by Rongrong Yan; Shuangfen Jin; Hongchao Liu; Chengjin Le; Jie Gao; Jing Cheng; Lin Chen; Na Li is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome about?

## Background: Osteosarcoma is a common malignant tumor in adolescents with a low 5-year survival rate. dexmedetomidine (dex) has been widely used for surgery of osteosarcoma patients. mir-520a-3p and yod1 expression was abnormal in osteosarcoma cells. however, whether dex affects osteosarcoma progression via mir-520a-3p-yod1 interactome needs to be explored. ## Methods: We detected osteosarcoma cells biological behavior by cck-8 assay, brdu assay, cell adhesion assay, and apoptosis assay, respectively. the mir-520a-3p and yod1 levels was explored in osteosarcoma cell lines by rt-qpcr or western blotting assay. ## Results: In this study, we found that dex treating osteosarcoma cells inhibited cell viability, proliferation and adhesion, while it promoted cell apoptosis. moreover, mir-520a-3p targeting to yod1 also functionally repressed cell malignancy in osteosarcoma cells. notably, dex treatment could inhibit yod1 expression via upregulating mir-520a-3p, thereby suppressing cell malignancy in osteosarcoma. ## Conclusions: Our study first revealed that dex inhibited malignancy of osteosarcoma cells via mir-520a-3p/yod1 axis.

Who reads Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome?

Author

Rongrong Yan; Shuangfen Jin; Hongchao Liu; Chengjin Le; Jie Gao; Jing Cheng; Lin Chen; Na Li

Publisher

Elsevier BV

Published

2021

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)